XML 71 R34.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Business segment information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2013
Segment Reporting [Abstract] |
Schedule of External Net Sales by SBU Reporting Segment | The table below presents external net sales by SBU reporting segment (amounts reported for prior periods have been reclassified to conform to our new segment reporting structure). Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of fees earned for the marketing of Trinity Evolution®, Trinity ELITE™ and Versashield® in our Biologics segment.
|  | External Net Sales by SBU |
|  | Three Months Ended September 30, |
(US$ in thousands) |  | 2013 |  |  | 2012 |  |  | Reported Growth |  |  | Constant Currency Growth |
|  |  |  |  | (Restated) |  |  | (Restated) |  |  | (Restated) |
BioStim |  | $ | 31,604 |  |  | $ | 42,310 |  |  |  | (25 | )% |  |  | (28 | )%
Biologics |  |  | 13,212 |  |  |  | 12,951 |  |  |  | 2 | % |  |  | 2 | %
Spine Fixation |  |  | 23,221 |  |  |  | 25,001 |  |  |  | (7 | )% |  |  | (7 | )%
Extremity Fixation |  |  | 24,701 |  |  |  | 27,595 |  |  |  | (10 | )% |  |  | (9 | )%
Total Net Sales |  | $ | 92,738 |  |  | $ | 107,857 |  |  |  | (14 | )% |  |  | (15 | )%
|  | External Net Sales by SBU |
|  | Nine Months Ended September 30, |
(US$ in thousands) |  | 2013 |  |  | 2012 |  |  | Reported Growth |  |  | Constant Currency Growth |
|  |  |  |  | (Restated) |  |  | (Restated) |  |  | (Restated) |
BioStim |  | $ | 108,445 |  |  | $ | 134,741 |  |  |  | (20 | )% |  |  | (20 | )%
Biologics |  |  | 39,827 |  |  |  | 39,792 |  |  |  | — | % |  |  | — | %
Spine Fixation |  |  | 71,994 |  |  |  | 72,972 |  |  |  | (1 | )% |  |  | (1 | )%
Extremity Fixation |  |  | 74,125 |  |  |  | 82,711 |  |  |  | (10 | )% |  |  | (8 | )%
Total Net Sales |  | $ | 294,391 |  |  | $ | 330,216 |  |  |  | (11 | )% |  |  | (11 | )%
Schedule of Contribution Margin From Continuing Operations by SBU Reporting Segment | The table below presents net margin, defined as gross profit less sales and marketing expenses, from continuing operations by SBU reporting segment:
Net margin by SBU |  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(US$ in thousands) |  | 2013 |  |  | 2012 |  |  | 2013 |  |  | 2012 |
|  |  |  |  | (Restated) |  |  |  |  |  | (Restated) |
Net margin: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
BioStim |  | $ | 10,614 |  |  | $ | 19,367 |  |  | $ | 45,911 |  |  | $ | 66,354 |
Biologics |  |  | 6,743 |  |  |  | 5,664 |  |  |  | 18,472 |  |  |  | 16,524 |
Spine Fixation |  |  | 1,227 |  |  |  | 4,693 |  |  |  | 7,489 |  |  |  | 13,379 |
Extremity Fixation |  |  | 8,321 |  |  |  | 11,145 |  |  |  | 21,766 |  |  |  | 24,508 |
Corporate |  |  | (469 | ) |  |  | (418 | ) |  |  | (1,376 | ) |  |  | (1,083 | )
Total net margin |  |  | 26,436 |  |  |  | 40,451 |  |  |  | 92,262 |  |  |  | 119,682 |
General and administrative |  |  | 13,202 |  |  |  | 13,850 |  |  |  | 46,736 |  |  |  | 42,715 |
Research and development |  |  | 6,361 |  |  |  | 6,858 |  |  |  | 20,653 |  |  |  | 23,160 |
Amortization of intangible assets |  |  | 616 |  |  |  | 565 |  |  |  | 1,725 |  |  |  | 1,725 |
Costs related to the accounting review and restatement |  |  | 2,664 |  |  |  |  |  |  |  | 2,664 |  |  |  |  |
Impairment of goodwill |  |  | 19,193 |  |  |  | — |  |  |  | 19,193 |  |  |  | — |
Charges related to U.S. Government resolutions |  |  | — |  |  |  | 373 |  |  |  | — |  |  |  | 1,059 |
Operating income (loss) |  | $ | (15,600 | ) |  | $ | 18,805 |  |  | $ | 1,291 |  |  | $ | 51,023 |

X
- Definition Contribution Margin by Segment Reporting [Table Text Block] + References No definition available. + Details
Name: | ofix_ContributionMarginBySegmentReportingTableTextBlock
Namespace Prefix: | ofix_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenues by reporting segment. + References No definition available. + Details
Name: | ofix_ScheduleOfSegmentReportingRevenuesBySegmentTableTextBlock
Namespace Prefix: | ofix_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration